NCT01242787View on ClinicalTrials.gov

Long-term Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B

PHASE2UnknownINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Chronic Hepatitis B
Interventions
DRUG

LB80380

Optimal dose of LB80380, by oral for 48 weeks (optimal dose will be chosen early 2011 based on the results of LG-BVCL007 study)

DRUG

Entecavir 0.5 mg

Entecavir 0.5 mg, by oral for 48 weeks

Trial Locations (2)

Unknown

Queen Mary Hospital, Hong Kong

Severance Hospital of Yonsei University and other 8 sites in Korea, Seoul

Sponsors

Lead Sponsor

LG Life Sciences
All Listed Sponsors
lead

LG Life Sciences

INDUSTRY

NCT01242787 - Long-term Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B | Biotech Hunter | Biotech Hunter